AlphaMab Oncology (09966) has announced that the first patient has been successfully dosed in a Phase I clinical study (Study Number: JSKN027-101) of JSKN027, the company's independently developed PD-L1/VEGFR2 bispecific antibody-drug conjugate (ADC). The trial is evaluating JSKN027 for the treatment of advanced malignant solid tumors. JSKN027 represents the fifth ADC candidate from the company to enter clinical studies and is the first PD-L1/VEGFR2 bispecific ADC globally to advance to this stage. Due to its multiple mechanisms of action, including cytotoxic killing, anti-angiogenesis, and immune regulation, JSKN027 holds the potential to offer new therapeutic options for various solid tumors. JSKN027-101 is an open-label, multicenter, Phase I clinical study conducted in subjects with advanced malignant solid tumors. The trial consists of two phases: dose escalation and dose expansion. Its primary objectives are to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of JSKN027 in patients with advanced malignant solid tumors, and to determine the maximum tolerated dose (MTD) and/or the recommended Phase II dose (RP2D).